Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link
Volume 13, Number 2—February 2007
Dispatch

Ertapenem Resistance of Escherichia coli

Marie-Frédérique Lartigue*, Laurent Poirel*, Claire Poyart†, Hélène Réglier-Poupet†, and Patrice Nordmann*Comments to Author 
Author affiliations: *Université Paris XI, Kremlin-Bicêtre, France; †Université Paris V, Paris, France;

Main Article

Table

MICs of β-lactam antimicrobial drugs for Escherichia coli CO, transconjugants pCO-1 and pCO-2, and reference strain E. coli J53*

β-lactamMIC (mg/L)
E. coli COTransconjugant pCO-1 (CTX-M-2)Transconjugant pCO-2 (OXA-10, TEM-1)E. coli J53
Amoxicillin>256>256>2562
Amoxicillin + CLA>2568642
Ticarcillin>256>256>2562
Ticarcillin + CLA>256321282
Piperacillin>256>256641
Piperacillin + TZB2562321
Cephalotin>256>25644
Cefoxitin256444
Ceftazidime6440.060.06
Ceftazidime + CLA10.1250.060.06
Cefotaxime>256640.060.06
Cefotaxime + CLA12810.060.06
Cefepime>256160.060.06
Moxalactam1280.060.060.06
Aztreonam>256320.060.06
Imipenem80.250.250.25
Meropenem80.060.060.06
Ertapenem>2560.030.030.03

*CLA, clavulanic acid at a fixed concentration of 2 mg/L; TZB, tazobactam at a fixed concentration of 4 mg/L..

Main Article

Page created: June 29, 2010
Page updated: June 29, 2010
Page reviewed: June 29, 2010
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.
file_external